感染性休克早期目标导向治疗:患者水平荟萃分析
该前瞻性设计的个体患者数据荟萃分析整合了ProCESS、ARISE和ProMISe三项多中心试验,共纳入7个国家138家医院的3723例感染性休克患者。主要终点90天死亡率EGDT组为24.9%(462/1852),常规治疗组为25.4%(475/1871),校正OR 0.97(95%CI 0.82–1.14;P=0.68)。EGDT组ICU使用天数(5.3±7.1 vs 4.9±7.0天,P=0.04)和心血管支持天数(1.9±3.7 vs 1.6±2.9天,P=0.01)更多,平均费用更高。亚组分析显示,休克更严重(乳酸更高、低血压合并高乳酸血症或预测死亡风险更高)的患者及常规复苏中血管加压药或液体使用倾向较低的医院,EGDT均无获益。
要点
- EGDT组90天死亡率24.9%(462/1852)与常规治疗组25.4%(475/1871)相似,校正OR 0.97(95%CI 0.82–1.14;P=0.68)。
- EGDT组ICU使用天数更多(5.3±7.1 vs 4.9±7.0天,P=0.04),心血管支持天数更多(1.9±3.7 vs 1.6±2.9天,P=0.01)。
- EGDT组平均住院费用高于常规治疗组。
- 休克更严重(乳酸更高、低血压合并高乳酸血症或预测死亡风险更高)的患者亚组中EGDT无获益。
- 常规复苏中血管加压药或液体使用倾向较低的医院,EGDT亦无获益。
适用人群与场景
- 三项多中心试验(ProCESS、ARISE、ProMISe)纳入的感染性休克患者,共3723例,来自7个国家138家医院。
- 亚组分析涵盖16项患者特征和6项医疗提供特征。
研究设计与关键结果
- 研究类型:三项多中心随机试验的个体患者数据荟萃分析,前瞻性设计,统一入组标准、干预方案、结局、资源使用指标和数据收集,并在揭盲前指定所有分析。
- 样本量与中心:3723例患者,138家医院,7个国家。
- 主要终点:90天死亡率EGDT组24.9%(462/1852)vs 常规治疗组25.4%(475/1871),校正OR 0.97(95%CI 0.82–1.14;P=0.68)。
- 次要终点:EGDT组ICU使用天数5.3±7.1 vs 常规治疗组4.9±7.0天(P=0.04);心血管支持天数1.9±3.7 vs 1.6±2.9天(P=0.01);其他结局无显著差异;EGDT组平均费用更高。
- 亚组分析:休克更严重(乳酸更高、低血压合并高乳酸血症或预测死亡风险更高)的患者及常规复苏中血管加压药或液体使用倾向较低的医院,EGDT无获益。
证据类型、等级与局限
- 证据类型:个体患者数据荟萃分析(基于三项多中心随机试验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在此个体患者数据荟萃分析中,EGDT较常规治疗未带来更好的结局,且在广泛的患者和医院特征中与更高的住院费用相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: After a single-center trial and observational studies suggesting that early, goal-directed therapy (EGDT) reduced mortality from septic shock, three multicenter trials (ProCESS, ARISE, and ProMISe) showed no benefit. This meta-analysis of individual patient data from the three recent trials was designed prospectively to improve statistical power and explore heterogeneity of treatment effect of EGDT.
METHODS: We harmonized entry criteria, intervention protocols, outcomes, resource-use measures, and data collection across the trials and specified all analyses before unblinding. After completion of the trials, we pooled data, excluding the protocol-based standard-therapy group from the ProCESS trial, and resolved residual differences. The primary outcome was 90-day mortality. Secondary outcomes included 1-year survival, organ support, and hospitalization costs. We tested for treatment-by-subgroup interactions for 16 patient characteristics and 6 care-delivery characteristics.
RESULTS: We studied 3723 patients at 138 hospitals in seven countries. Mortality at 90 days was similar for EGDT (462 of 1852 patients [24.9%]) and usual care (475 of 1871 patients [25.4%]); the adjusted odds ratio was 0.97 (95% confidence interval, 0.82 to 1.14; P=0.68). EGDT was associated with greater mean (±SD) use of intensive care (5.3±7.1 vs. 4.9±7.0 days, P=0.04) and cardiovascular support (1.9±3.7 vs. 1.6±2.9 days, P=0.01) than was usual care; other outcomes did not differ significantly, although average costs were higher with EGDT. Subgroup analyses showed no benefit from EGDT for patients with worse shock (higher serum lactate level, combined hypotension and hyperlactatemia, or higher predicted risk of death) or for hospitals with a lower propensity to use vasopressors or fluids during usual resuscitation.
CONCLUSIONS: In this meta-analysis of individual patient data, EGDT did not result in better outcomes than usual care and was associated with higher hospitalization costs across a broad range of patient and hospital characteristics. (Funded by the National Institute of General Medical Sciences and others; PRISM ClinicalTrials.gov number, NCT02030158 .).
参考来源
- Rowan KM, Angus DC, Bailey M, et al. Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. N Engl J Med. 2017. PMID: 28320242. doi:10.1056/NEJMoa1701380
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。